Second line small molecule therapy options for treating chronic myeloid leukemia

Area of Science:

• Hematology
• Oncology
• Pharmacology

Background:

• Approximately 33% of chronic myeloid leukemia (CML) patients discontinue imatinib therapy due to resistance or intolerance.
• Second-generation TKIs (dasatinib, nilotinib, bosutinib) and third-generation ponatinib have complicated CML treatment.
• Newer agents targeting different mechanisms are under development for resistant CML.

Purpose of the Study:

• To review the efficacy of second-line small molecule inhibitors for CML.
• To discuss the safety profiles of these agents.
• To highlight the need for individualized treatment strategies.

Main Methods:

• Review of clinical trial data for second- and third-generation TKIs.
• Analysis of drug efficacy against BCR-ABL1 mutations.
• Evaluation of safety profiles and emerging side effects.

Main Results:

• Second-generation TKIs are effective against imatinib-resistant/intolerant CML, except for the T315I mutation.
• Ponatinib is active against all BCR-ABL1 mutants, including T315I.
• Distinct safety profiles necessitate patient stratification based on comorbidities and cardiovascular risk.

Conclusions:

• Individualized second-line TKI treatment is essential, considering patient-specific factors.
• Future CML treatment may involve drug combinations to overcome resistance.
• Ongoing research aims to provide alternatives for patients resistant to ATP-binders.